1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,340 | 1,360 | 29.07. | |
| 1,320 | 1,380 | 29.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial | 8.716 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| Fr | NanoViricides announces $3.8M registered direct offering; shares down | 5 | Seeking Alpha | ||
| Fr | NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering | 1.281 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 22.07. | As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola | 8.492 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 17.07. | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.07. | As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo | 584 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 08.07. | Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily | 617 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a... ► Artikel lesen | |
| 06.07. | Noble Capital startet Coverage für NanoViricides mit "Outperform" | 1 | Investing.com Deutsch | ||
| 06.07. | Noble Capital initiates NanoViricides stock with Outperform rating | 3 | Investing.com | ||
| 06.07. | As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo | 529 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it... ► Artikel lesen | |
| 29.06. | NanoViricides: US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher | 737 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 22.06. | NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo | 987 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical... ► Artikel lesen | |
| 15.06. | As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo | 1.077 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides... ► Artikel lesen | |
| 08.06. | As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies | 807 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides... ► Artikel lesen | |
| 26.05. | In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides | 849 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential... ► Artikel lesen | |
| 20.05. | NANOVIRICIDES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.05. | NanoViricides Announces Closing of ~$2 Million Registered Direct Offering | 831 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 18.05. | Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides | 894 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the... ► Artikel lesen | |
| 15.05. | NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering | 637 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 15.05. | NanoViricides GAAP EPS of -$0.09 | 3 | Seeking Alpha |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 19,180 | +2,46 % | Druck auf Formycon nimmt zu: Das Muster kennen erfahrene Anleger nur zu gut - Hier trennt sich die Spreu vom Weizen | ||
| ONTO INNOVATION | 197,40 | -7,06 % | Onto Innovation (ONTO) Dips More Than Broader Market: What You Should Know | ||
| GOMSPACE | 1,113 | +1,74 % | GomSpace A/S: GomSpace Signs 24.4 MSEK Contract with Unseenlabs | Unseenlabs extends its existing cube satellites constellation.STOCKHOLM, July 1, 2026 /PRNewswire/ -- Today, GomSpace has signed an additional contract with Unseenlabs to deliver two new... ► Artikel lesen | |
| NVE | 100,00 | -2,91 % | Morning Market Movers: 707 Cayman, Zhongchao, NVE Corporation, Medpace See Big Swings | BEIJING (dpa-AFX) - At 8:25 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VEECO INSTRUMENTS | 37,480 | -6,60 % | Metal Powder Works (ASX:MPW) hires a Veeco operator to turn qualification into commercial production | ||
| KOPIN | 2,850 | -7,95 % | Fabric.AI (Nasdaq: FABC) Stockholders Ratify Kopin Strategic Partnership to Develop Neural I/o MicroLED Optical Interconnect Technology for Next Generation AI Data Centers | NEW YORK, NY, June 24, 2026 (GLOBE NEWSWIRE) -- Fabric.AI, Inc. (Nasdaq: FABC) ("Fabric.AI" or the "Company"), a fabless semiconductor company developing MicroLED-based optical interconnects for AI... ► Artikel lesen | |
| RIBER | 8,670 | -1,25 % | RIBER: FIRST-HALF 2026 BUSINESS ACTIVITY Business growth, resilient order book and continued rollout of ROSIE | FIRST-HALF 2026 BUSINESS ACTIVITYBusiness growth, resilient order book and continued rollout of ROSIE Bezons, July 22, 2026 - 8:00 am - RIBER, the global leader in molecular beam epitaxy (MBE) equipment... ► Artikel lesen | |
| SMOLTEK NANOTECH | 0,105 | -2,78 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.06.2026 | Das Instrument G85 CA35958L1013 FUERTE METALS CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 09.06.2026 und ex Kapitalmassnahme am 10.06.2026 The instrument G85 CA35958L1013 FUERTE METALS CORP.... ► Artikel lesen | |
| SOLESENCE | 0,920 | -1,04 % | Solésence, Inc.: Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results | Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty... ► Artikel lesen | |
| GAUZY | 0,310 | -4,65 % | Smart glass co Gauzy seeks debt settlement | ||
| NANOVEU | 0,046 | +15,00 % | Nanoveu (ASX:NVU) lands Bosch Sensortec and the ECS-DoT platform thesis gets teeth | ||
| OBDUCAT | 0,053 | -20,18 % | NGM MARKET NOTICE: #26-16 Information regarding the last day of trading in paid subscribed units and the first day of trading in warrants issued by Obducat AB | ||
| ACACIA RESEARCH | 3,980 | 0,00 % | ACACIA RESEARCH CORP - 8-K, Current Report | ||
| ADVANCE ZINCTEK | 0,416 | -2,35 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | ||
| LAMPETIA | 0,154 | 0,00 % | EQS-Adhoc: Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten | EQS-Ad-hoc: Lampetia AG / Schlagwort(e): Sonstiges
Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten
16.07.2026 / 22:00 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-1,44 %) liegt der Kurs bei 1,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.